Analysis and reporting of adverse events in randomised controlled trials: a review

被引:134
|
作者
Phillips, Rachel [1 ]
Hazell, Lorna [2 ,3 ]
Sauzet, Odile [4 ]
Cornelius, Victoria [1 ]
机构
[1] Imperial Coll London, Fac Med, Sch Publ Hlth, London, England
[2] Drug Safety Res Unit, Clin Res, Southampton, Hants, England
[3] Univ Portsmouth, Dept Pharm & Biomed Sci, Portsmouth, Hants, England
[4] Univ Bielefeld, Epidemiol & Int Publ Hlth, Fac Hlth Sci, Bielefeld, Germany
来源
BMJ OPEN | 2019年 / 9卷 / 02期
关键词
CLINICAL-TRIALS; SAFETY DATA; THERAPY; ERYTHROPOIETIN; CHILDREN; INSULIN; ASPIRIN; PLACEBO;
D O I
10.1136/bmjopen-2018-024537
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To ascertain contemporary approaches to the collection, reporting and analysis of adverse events (AEs) in randomised controlled trials (RCTs) with a primary efficacy outcome. Design A review of clinical trials of drug interventions from four high impact medical journals. Data sources Electronic contents table of the BMJ, the Journal of the American Medical Association (JAMA), the Lancet and the New England Journal of Medicine (NEJM) were searched for reports of original RCTs published between September 2015 and September 2016. Methods A prepiloted checklist was used and single data extraction was performed by three reviewers with independent check of a randomly sampled subset to verify quality. We extracted data on collection methods, assessment of severity and causality, reporting criteria, analysis methods and presentation of AE data. Results We identified 184 eligible reports (BMJ n=3; JAMA n=38, Lancet n=62 and NEJM n=81). Sixty-two per cent reported some form of spontaneous AE collection but only 29% included details of specific prompts used to ascertain AE data. Numbers that withdrew from the trial were well reported (80%), however only 35% of these reported whether withdrawals were due to AEs. Results presented and analysis performed was predominantly on 'patients with at least one event' with 84% of studies ignoring repeated events. Despite a lack of power to undertake formal hypothesis testing, 47% performed such tests for binary outcomes. Conclusions This review highlighted that the collection, reporting and analysis of AE data in clinical trials is inconsistent and RCTs as a source of safety data are underused. Areas to improve include reducing information loss when analysing at patient level and inappropriate practice of underpowered multiple hypothesis testing. Implementation of standard reporting practices could enable a more accurate synthesis of safety data and development of guidance for statistical methodology to assess causality of AEs could facilitate better statistical practice.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] The reporting of outcomes in randomised controlled trials
    Ghert, M.
    BONE & JOINT RESEARCH, 2017, 6 (10): : 600 - 601
  • [32] Reporting bias in randomised controlled trials
    不详
    EJHP PRACTICE, 2010, 16 (03): : 16 - 16
  • [33] Tocilizumab and the risk of respiratory adverse events in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised controlled trials
    Geng, Z.
    Yu, Y.
    Hu, S.
    Dong, L.
    Ye, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (02) : 318 - 323
  • [34] A systematic review and meta-analysis evaluating the risk of central nervous system adverse events in randomised controlled trials of dolutegravir
    Chowdhury, K. M.
    Hill, A. M.
    HIV MEDICINE, 2019, 20 : 94 - 94
  • [35] Acute and late adverse events associated with radical prostate cancer treatment: A systematic review of clinician and patient toxicity reporting in randomised controlled trials (RCT).
    Holch, Patricia
    Henry, Ann
    Davidson, Susan
    Gilbert, Alexandra
    Routledge, Jacki
    Shearsmith, Leanne
    Franks, Kevin
    Ingleson, Emma
    Allbut, Abigail
    Velikova, Galina
    PSYCHO-ONCOLOGY, 2016, 25 (SP. S3) : 179 - 180
  • [36] Prospective reporting of statistical analysis plans for randomised controlled trials
    Hemming, Karla
    Kearney, Anna
    Gamble, Carrol
    Li, Tianjing
    Juni, Peter
    Chan, An-Wen
    Sydes, Matthew R.
    TRIALS, 2020, 21 (01)
  • [37] Prospective reporting of statistical analysis plans for randomised controlled trials
    Karla Hemming
    Anna Kearney
    Carrol Gamble
    Tianjing Li
    Peter Jüni
    An-Wen Chan
    Matthew R. Sydes
    Trials, 21
  • [38] Reporting of adverse effects in randomised clinical trials of chiropractic manipulations: a systematic review
    Ernst, Edzard
    Posadzki, Paul
    NEW ZEALAND MEDICAL JOURNAL, 2012, 125 (1353) : 87 - 140
  • [39] Reporting of social deprivation in musculoskeletal trials: An analysis of 402 randomised controlled trials
    Smith, Toby O.
    Kamper, Steven J.
    Williams, Christopher M.
    Lee, Hopin
    MUSCULOSKELETAL CARE, 2021, 19 (02) : 180 - 185
  • [40] Analysis of recurrent events: a systematic review of randomised controlled trials of interventions to prevent falls
    Donaldson, Meghan G.
    Sobolev, Boris
    Cook, Wendy L.
    Janssen, Patti A.
    Khan, Karim M.
    AGE AND AGEING, 2009, 38 (02) : 151 - 155